Crescent Capital BDC, Inc. (NASDAQ:CCAP – Get Rating) CEO Jason Breaux bought 2,800 shares of Crescent Capital BDC stock in a transaction on Thursday, May 12th. The shares were purchased at an average cost of $17.09 per share, for a total transaction of $47,852.00. Following the completion of the purchase, the chief executive officer now directly owns 41,592 shares of the company’s stock, valued at $710,807.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Crescent Capital BDC stock opened at $17.01 on Friday. The company has a fifty day simple moving average of $17.69 and a 200-day simple moving average of $18.15. Crescent Capital BDC, Inc. has a 12-month low of $16.58 and a 12-month high of $21.48. The company has a current ratio of 0.80, a quick ratio of 1.37 and a debt-to-equity ratio of 0.96. The stock has a market cap of $525.44 million, a price-to-earnings ratio of 6.30, a PEG ratio of 0.85 and a beta of 0.88.
Crescent Capital BDC (NASDAQ:CCAP – Get Rating) last issued its earnings results on Wednesday, February 23rd. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.01. Crescent Capital BDC had a net margin of 78.46% and a return on equity of 7.88%. The business had revenue of $24.14 million during the quarter, compared to analysts’ expectations of $24.24 million. On average, analysts forecast that Crescent Capital BDC, Inc. will post 1.66 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Crescent Capital BDC from a “hold” rating to a “sell” rating in a research note on Tuesday, April 26th. Bank of America assumed coverage on shares of Crescent Capital BDC in a research note on Monday, January 31st. They issued a “buy” rating and a $19.50 price target on the stock. Finally, Wells Fargo & Company reduced their price target on shares of Crescent Capital BDC from $19.50 to $18.50 and set an “overweight” rating on the stock in a research note on Monday, April 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Crescent Capital BDC has an average rating of “Hold” and an average price target of $19.70.
A number of hedge funds have recently added to or reduced their stakes in CCAP. Captrust Financial Advisors purchased a new position in Crescent Capital BDC during the 3rd quarter worth $103,000. JPMorgan Chase & Co. purchased a new position in Crescent Capital BDC during the 1st quarter worth $185,000. LPL Financial LLC purchased a new position in Crescent Capital BDC during the 4th quarter worth $190,000. Comerica Bank purchased a new position in Crescent Capital BDC during the 3rd quarter worth $215,000. Finally, Eagle Global Advisors LLC purchased a new position in Crescent Capital BDC during the 4th quarter worth $222,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.
Crescent Capital BDC Company Profile (Get Rating)
Crescent Capital BDC, Inc is a business development company. The fund focuses on originating and investing in the debt of middle market companies. It typically focuses on companies based in United States.
- Get a free copy of the StockNews.com research report on Crescent Capital BDC (CCAP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Crescent Capital BDC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Capital BDC and related companies with MarketBeat.com's FREE daily email newsletter.